Riskpilot← Back to searchSign inGet full accessNextPharma Oy
OYActiveY-tunnus 2968177-8Niittyhaankatu 20Manufacture of pharmaceutical preparations · NACE 2120Est. 2019225 employees
Revenue 2024
EUR 31,3M
+5% vs 2023
EBITDA margin
8.7%
-12% vs 2023
Equity ratio
31.4%
Financial strength
Net profit 2024
EUR 60K
+601210% vs 2023
| Revenue | EUR 31,3M | +5% |
| EBITDA | EUR 2,7M | -12% |
| Net profit | EUR 60K | +601210% |
| Total assets | EUR 36,9M | +20% |
| Equity | EUR 11,6M | +1% |
| Employees | 225 | — |
Legal name
NextPharma Oy
Y-tunnus number
2968177-8
Legal form
Osakeyhtiö
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
16. tammikuuta 2019
Share capital
EUR 2 500
Employees
225 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen jäsenet ja toimitusjohtaja kukin yksin
Company purpose
Yhtiön toimialana on lääkealan sopimusvalmistus ja tuotekehitys.
Address
Niittyhaankatu 20
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 31 293 | 24 524 | 30 190 | 29 958 | 31 347 |
| Staff expenses | −10 590 | −8 595 | −9 163 | −10 949 | −12 230 |
| EBITDA | 6 926 | 3 496 | 14 488 | 3 093 | 2 726 |
| Depreciation & amort. | −241 | −343 | −1 098 | −1 538 | −1 620 |
| EBIT | 6 685 | 3 153 | 13 390 | 1 555 | 1 107 |
| Net financials | −928 | −870 | −998 | −678 | −561 |
| Profit before tax | 5 543 | 2 119 | 7 904 | −995 | 75 |
| Tax | 1 112 | 424 | 1 584 | −8 | 15 |
| Net profit | 4 431 | 1 695 | 6 320 | 0 | 60 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 21 471 | 25 434 | 36 857 | 30 708 | 36 895 |
| Equity | 4 930 | 6 756 | 16 666 | 11 520 | 11 580 |
| Long-term debt | 10 055 | 13 038 | 13 198 | 6 951 | 10 246 |
| Short-term debt | 6 486 | 5 640 | 6 993 | 5 186 | 7 548 |
| Total debt | 16 541 | 18 678 | 20 191 | 12 137 | 17 794 |
EBITDA margin
8.7%
This company
15.8%
Market median
-45% vs market
20202024
Equity ratio
31.4%
This company
38.2%
Market median
+18% vs market
20202024
Return on equity
0.5%
This company
18.4%
Market median
-97% vs market
20202024
Net profit margin
0.2%
This company
8.1%
Market median
-98% vs market
20202024
Asset turnover
0.85×
This company
1.12×
Market median
+24% vs market
20202024
Debt / equity
2.19×
This company
0.62×
Market median
-253% vs market
20202024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (7) | ||
OA Confidential Clerk | Confidential Clerk | 2025 |
UI Confidential Clerk | Confidential Clerk | 2020 |
AK Chief Executive Officer | Chief Executive Officer | 2026 |
SS Confidential Clerk | Confidential Clerk | 2025 |
ST Confidential Clerk | Confidential Clerk | 2021 |
EZ Confidential Clerk | Confidential Clerk | 2025 |
AO Confidential Clerk | Confidential Clerk | 2025 |
| Former (9) | ||
PT Confidential Clerk | Confidential Clerk | 2020 – 2021 |
LT Confidential Clerk | Confidential Clerk | 2019 – 2020 |
MJ | Audit | 2022 – 2023 |
JI Confidential Clerk | Confidential Clerk | 2022 – 2025 |
LI Audit | Audit | 2019 – 2022 |
PA Chief Executive Officer | Chief Executive Officer | 2019 – 2026 |
KS Confidential Clerk | Confidential Clerk | 2019 – 2025 |
KH Confidential Clerk | Confidential Clerk | 2020 – 2022 |
MJ Confidential Clerk | Confidential Clerk | 2019 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2019 | |
| Board of Directors | 2022 | |
| Former (1) | ||
| Board of Directors | 2019 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of NextPharma Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Otto Aki Juhani Sinkkonen | Confidential Clerk | 0 companies |
| Paula Tuulikki Havu | Confidential Clerk | 0 companies |
| Ulla Irmeli Salminen | Confidential Clerk | 0 companies |
| Lasse Tapio Heinonen | Confidential Clerk | 0 companies |
| Miikka Juha-Hermanni Hietala | Audit | 0 companies |
| Ajeeth Kumar Enjeti | Chief Executive Officer | 0 companies |
| Jouni Ilmari Kusnetsoff | Confidential Clerk | 0 companies |
| Lotta Irina Nurminen | Audit | 0 companies |
| Peter Arend William Burema | Chief Executive Officer | 0 companies |
| Katri Sinikka Outinen | Confidential Clerk | 0 companies |
| Stefan Sander Weber | Confidential Clerk | 0 companies |
| Satu Tiina Marjaana Särkkä | Confidential Clerk | 0 companies |
| Kati Hannele Sällinen | Confidential Clerk | 0 companies |
| Matti Johannes Rosengren | Confidential Clerk | 0 companies |
| Edwin-Oswald Zachari | Confidential Clerk | 0 companies |
| Arttu-Pekka Oskari Mäkinen | Confidential Clerk | 0 companies |
| Eric Carsten Schmidhäuser | Board of Directors | 0 companies |
| Frank Posnanski | Board of Directors | 0 companies |
| William Mark Hawkins | Board of Directors | 0 companies |